Metabolomics provide a further guide to the development of precision therapies in ALS

A key facet for the establishment of tailored intervention strategies directed against disease relates to the identification of patient subgroups and phenotypes which may then be utilised to predict individual treatment response and suggest future care approaches. Comprehensive clinical phenotyping is essential to reach an early and accurate diagnosis, and for mapping subsequent patterns of progression.1 It further serves to identify correlation between the variables of clinical presentation and disease burden, potentially enabling biomarker development.2 In turn, comprehensive patient phenotyping may assist in the stratification necessary to identify which patients may benefit most from a specific intervention.3 With these concepts in mind, the study by Goutman and colleagues delineates a role for advanced metabolomic analyses to gain insight into …